February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?

Hosted by:  Warner K. Huh, MD, FACOG, FACS, Deputy Editor of Gynecologic Oncology Featuring: Elizabeth Swisher, MD, UW Medicine Jonathan A Ledermann, MD FRCP FMedSci Professor of Medical Oncology, UCL Cancer Institute Editor’s Choice Paper: Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study Editorial: Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?